|Contents of Shopping Cart|
Which of the following is the principal side effect of Zaltrap?
c. G.I perforation and bleeding
d. Ocular hypertension
Answer:(c). Ziv-aflibercept (Zaltrap) is a recombinant fusion protein consisting of Vascular Endothelial Growth Factor (VEGF)-binding portions from the extracellular domains of human VEGF Receptors 1 and 2 fused to the Fc portion of the human IgG1.
Ziv-aflibercept (Zaltrap), in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.
Administer Ziv-aflibercept (Zaltrap) 4 mg per kg as an intravenous (IV) infusion over 1 hour every two weeks. Administer Ziv-aflibercept (Zaltrap) prior to any component of the FOLFIRI regimen on the day of treatment.
Severe and sometimes fatal hemorrhage, including gastrointestinal (GI) hemorrhage, has been reported in the patients who have received Ziv-aflibercept (Zaltrap) in combination with FOLFIRI. Monitor patients for signs and symptoms of GI bleeding and other severe bleeding. Do not administer Ziv-aflibercept (Zaltrap) to patients with severe hemorrhage.
Gastrointestinal Perforation: Gastrointestinal (GI) perforation including fatal GI perforation can occur in patients receiving Ziv-aflibercept (Zaltrap). Discontinue Ziv-aflibercept (Zaltrap) therapy in patients who experience GI perforation.
Severe compromised wound healing can occur in patients receiving ZALTRAP/FOLFIRI. Discontinue Ziv-aflibercept (Zaltrap) in patients with compromised wound healing. Suspend Ziv-aflibercept (Zaltrap) for at least 4 weeks prior to elective surgery, and do not resume Ziv-aflibercept (Zaltrap) for at least 4 weeks following major surgery and until the surgical wound is fully healed.
www.pharmacyexam.com Try our Naplex Questions QBank.